The analysis, published online this month by the journal Health Affairs, appears to refute critics who have charged the Food and Drug Administration is less efficient than the European Medicines Agency and has been slower to approve new cancer drugs.
The study’s authors compiled a list of 35 new cancer drugs approved by either of the agencies between 2003 and 2010. They found that the F.D.A. had approved 32 of the products in an average of 182 days from the time that the first
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment